Lessons from the Heart of Soweto Study and future directions by Pretorius, Sandra et al.
Lessons from the  
Heart of Soweto Study  
and future directions
the overburdened healthcare service providers in South Africa 
struggle to cope, strategies to prevent chronic diseases of life- 
style (CDL) risk factors remain a low priority and adequate care 
and prevention of CDL are becoming an increasing public health 
issue.(4,6)
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tHE HEArt of 
SowEto Study
IntroductIon                                                                
The socio-economic status and development of a country have a 
direct impact on the mortality and morbidity of its people.(1) With 
industrialisation, disease patterns have changed from being domi-
nated by nutritional deficiencies and infectious disease, to chronic 
diseases of lifestyle, such as cardiovascular disease (CVD), hyper-
tension, cancer and diabetes. This change has become known as 
“the epidemiological transition”.(1) Countries around the world are 
however, affected differently, with developing countries, such as 
South Africa, being at a different stage of epidemiological transition 
compared to the more developed and affluent countries.(1,2)
South Africa is concurrently experiencing epidemiological transition 
with diseases of lifestyle on the increase, while still being burdened 
by poverty related diseases as well.(3) In fact, South Africa faces a 
quadruple burden of disease, characterised by a combination of 
poverty-related diseases, emerging chronic diseases of lifestyle, high 
injury rates, as well as the human immunodeficiency virus or 
acquired immunodeficiency syndrome (HIV/AIDS) pandemic.(3-6) As 
south Africa is concurrently experiencing epidemiological 
transition with diseases of lifestyle on the increase, while still 
burdened by poverty related diseases. chronic diseases of 
lifestyle such as cVd are rapidly becoming major causes of 
death in developing countries and by all predictions, will 
continue rising.(4,7,8,9) of concern is the fact that in developing 
countries, cVd is occurring in younger individuals than in 
the developed countries and as the epidemic evolves, the 
poor are affected the most in both developed and developing 
countries.(1) the Heart of soweto (Hos) study aimed to 
investigate and describe this emerging problem of cVd, 
and especially heart disease, amongst the urban African 
population in soweto, who presented for the first time to a 
tertiary-care centre. overall we found multiple challenges 
to the community of soweto and surrounding regions from 
a combination of high levels of modifiable cV risk factors 
(with the exception of lipid disorders) and surprisingly high 
levels of advanced and deadly forms of heart disease affecting 
predominantly younger cases and women. Lessons learned 
from the Hos include, (1) building partnerships, (2) establish 
clear objectives with achievable goals, (3) think big and 
assume nothing, (4) provide an enabling environment, (5) be 
innovative and (6) never compromise on quality.
the prevention of cVd other chronic diseases of lifestyle, as 
well as the management thereof, needs to be a multi-
disciplinary effort with all the necessary healthcare workers 
involved, implemented at the primary, as well secondary 
level. our goal is the development of specific community-
based intervention programmes directed towards preven-
tion and management of chronic diseases of lifestyle in 
soweto and to document the aetiology, presentation and 
management thereof. our data collection will be not only 
meaningful for the population in soweto, but also in other 
areas of south Africa and the broader Africa. It will be 
indicative of any urban African population in transition. 
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Chronic diseases of lifestyle, such as CVD, are rapidly becoming 
major causes of death in developing countries. According to the 
South African National Burden of Disease, CDL were the leading 
cause of death, followed by HIV/AIDS, injuries and other infectious 
diseases in the year 2000, and the prediction is that CVD might 
be increasing by approximately 150% by the year 2020.(4,7,8,9) It can 
be expected that in the early stages of the transition, people in 
higher socio-economic positions will carry the highest risk of 
CVD and other NCDs. However, indications are that as this tran-
sition progresses in developing countries, it is the most vulnerable 
members of society, the poor, who are affected the most.(8,10)
Of concern is the fact that in developing countries, CVD is occur-
ring in younger individuals than in the developed countries and as 
the epidemic advances, the poor are affected the most in both 
developed and developing countries.(1) Poverty cannot be described 
in simplistic terms, because it is a multidimensional phenomenon 
with ideological and political, governance, social, economic, environ-
mental and biological (health) components. It is often characterised 
by a lack of freedom, education, capabilities, opportunities, employ-
ment and equity and results in insufficient sanitation and food 
supply that leads to malnutrition (both under- and over-nutrition), 
and increases the risk for developing CVD. The effect of this is felt 
most by communities with low socio-economic status and living in 
urban areas.(3,8,11) 
Soweto                                                                           
The South Western Township, later named Soweto, was developed 
in the proximity of Johannesburg, South Africa, approximately 100 
years ago. It is home to one of the largest number of urban black 
Africans on the African continent.(4,12) According to an official 
census done in 2001, the number of people living in Soweto was 
approximately 1 million people. This number is rising, as there is 
a steady influx of migrants.(13) It is a population in transition, with 
old squatter misery and new prosperity existing side by side.(4,12)
Data on the population of Soweto has shown a low prevalence for 
CVD and the underlying risk factors.(4) This might however be 
changing, as several studies have shown that urbanisation and the 
nutrition transition in South Africa is accompanied by an increase in 
the CVD risk factors in those of African descent. More data is 
however needed to determine whether this increase in CVD risk is 
related to urbanisation per se, or whether socio-economic position 
influences the nutrition transition and related increase in CVD 
risk.(8) The World Health Organisation (WHO) has estimated that 
people living in developing countries, such as South Africa will be 
affected twice as much, and even more, by non-communicable 
disease than in developed countries, with poor people living in 
urban settings being the most vulnerable, thereby increasing 
demand for chronic disease care and prevention.(11)
Thus, studies to investigate the emergence of heart disease in 
developing countries and among risk populations like the pre-
dominantly African, urban population of South Africa are of 
extreme importance. 
the Heart of Soweto Study
The Heart of Soweto (HOS) study was established at Chris Hani 
Baragwanath Hospital, Soweto, South Africa. The aim of the HOS 
study was to investigate and to describe this emerging problem of 
CVD, and especially heart disease, amongst the urban African 
population in Soweto, who presented for the first time to a tertiary-
care centre.(6)
This ongoing project has confirmed our worst fears in terms of 
the CV risk profile of this community in epidemiological transition 
and the likely consequences in terms of deadly forms of advanced 
disease. Through a monthly series of “Heart Awareness Days” we 
undertook community screening of voluntary adult participants in 
Soweto (>1 500 subjects in total) and found that only 22% of 
participants had no risk factor for CVD. Moreover, awareness rates 
of heart disease and its risk factors were extremely low. The most 
prevalent CV risk factor by far was obesity (43%), while up to 70% 
were overweight; an observation that is consistent with other 
community-based surveys in the region, with far more obese 
women than men (23% versus 55%: OR 0.24 95% CI 0.19 to 
0.30: p <0.001). The fundamental importance of this finding should 
be emphasised. In a culture where low weight is either associated 
with the stigma of malnutrition or, worse, HIV/AIDS, it is difficult 
to educate individuals and the wider community about the dangers 
of excess weight. Indeed, the general lack of weigh scales both in 
the homes and healthcare facilities of Soweto are a major chal-
lenge in managing obesity even when an individual is committed 
to losing weight. A further 33% of subjects in the “Heart Aware- 
ness Days” recorded elevated blood pressures whilst 13% of 
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participants recorded an elevated (non-fasting) total blood choles-
terol level with minimal difference between men and women 
observed in this regard. Consistent with the importance of our 
findings in relation to the weight profile of participants, being 
either overweight or obese was significantly associated with ele-
vated blood pressure, and raised cholesterol levels.(13)
In addition to monitoring risk factors at the community level, 
within the constraints of limited resources and a chaotic township 
environment that prevented a more orthodox approach to risk 
surveillance, we established an advanced clinical registry for all 
patients attending the Cardiology Unit of the Baragwanath Hospital 
servicing Soweto and surrounding communities.(6) In 2006, this 
registry captured a combination of demographic, clinical, investi-
gative and treatment data from 4 162 new and returning patients. 
The majority of new presentations (n = 1 593 / 38% of all cases) 
were subject to a systematic screening  programme with an echo-
cardiograph. Overall, we found a broad range of CVD (pre-
dominantly advanced heart disease) in the 1 593 new cases that 
comprised mainly black Africans (85%) and women (60%); the 
latter being slightly younger than men (mean age 53 ± 16 vs. 55 
± 15 years: p = 0.031) with almost a quarter of cases aged <40 
years old overall. Data from the HOS showed that CVD risk 
factors was high, with 56% of cases diagnosed with hypertension 
(47% of which were also obese) and almost two thirds having 
multiple risk factors. Compared to the rest of the cohort, those of 
African descent were far more likely to be diagnosed with HF 
(OR 2.36, 95% CI 1.74 to 3.21: p <0.0001) but far less likely to 
be diagnosed with coronary artery disease (OR 0.10, 95% CI 0.07 
to 0.14: p <0.0001). Apart from the 310 cases (19%) with a primary 
diagnosis of hypertension, most were “late” clinical presentations 
with established heart disease and multiple etiologies. The four 
most common diagnoses overall were hypertension (total of 897 
cases – 56%), HF (844 cases – 53%), valvular heart disease/dys-
function (360 cases – 23%) and coronary artery disease (165 
cases – 10%) (Figure 1). Those patients diagnosed with valvular 
heart disease being on average more than a decade younger than 
the remainder of cases. A further 10% of cases were diagnosed 
with concurrent diabetes and/or renal disease. Perhaps due to the 
fact that this was an urban population and the focus on cardiologic 
cases, the number of stroke presentations was low: overall 145 
patients (9.1%) reported a family history of stroke but there were 
only 64 cases (4.0%) of acute stroke or stroke as a secondary 
diagnosis.(14)
In contrast to a lack of stroke cases, it was clear that advanced 
cases of HF was a major feature of this study cohort. Consistent 
with the overall pattern of presentations, black Africans pre-
dominated (88% of cases); being far more likely to be diagnosed 
with HF (OR 2.36, 95% CI 1.74 to 3.21: p <0.0001) but far less 
likely to be diagnosed with CAD (OR 0.10, 95% CI 0.07 to 
0.14: p <0.0001).(12) In contrast to reports from high-income 
countries,(4-6) of the patients attending the cardiology clinic at 
Chris Hani Baragwanath Hospital, there were more women than 
men (57% of cases) and the average age on presentation was 55 
± 16 years. The most common forms of HF were hypertensive HF 
(281 [33%]), idiopathic dilated CMO (237 [28%]) and, surprisingly, 
right HF (225 [27%]). Black Africans had less ischaemic CMO 
(adjusted OR 0.12, 95% CI 0.07 to 0.20) but more idiopathic and 
other causes of CMO (adjusted OR 4.80, 95% CI 2.57 to 8.93). 
Overall, 180 (23%) patients had isolated diastolic dysfunction, 234 
(28%) tricuspid regurgitation, 121 (14%) isolated right HF and 100 
(12%) mitral regurgitation.(12) Consistent with a different pattern of 
HF when compared to high income countries,(15) concurrent renal 
dysfunction, anaemia and atrial fibrillation were found in relatively 
fewer cases overall representing 172 (25%), 72 (10%) and 53 
(6.3%) cases, respectively.(16)  
In addition to establishing and evaluating dedicated management 
programmes to specifically focus on the many patients who present 
with advanced heart disease in Soweto, as part of the HOS, we 
have initiated a specific programme of research that addresses the 
potential interaction between HIV/AIDS, its treatment (highly 
active antiretroviral therapy – HAART) and CVD. As such, South 
Africa is not only facing an epidemic of CVD but also suffering 
from the current HIV pandemic with an estimated 5 million 
South Africans infected, 1 million having AIDS and 500 000 
HIV-related deaths annually.(17) Infection itself may predispose to 
premature atherosclerosis through endothelial dysfunction, a 
heightened pro-inflammatory state and dyslipidaemia.(18) After a 
slow start, South Africa has since 2004, started HAART on more 
than 500 000 patients. Currently, Johannesburg and Soweto have 
one of the most effective implementation programmes. Para-
doxically, from a treatment perspective, protease inhibitors have 
the potential to induce an adverse metabolic phenotype including 
dyslipidaemia and insulin resistance, endothelial dysfunction and a 
prothrombotic state leading to atherosclerosis.(18) However, this has 
not been examined systematically in a larger population in Africa. 
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Data are urgently needed to be able to plan cost-effective screening 
and management strategies to combat the interaction between the 
two different but contemporary epidemics in low- to middle-
income countries.
Overall, therefore, we found multiple challenges for the community 
of Soweto and surrounding regions, from a combination of high 
levels of modifiable CV risk factors (with the exception of lipid 
disorders) and surprisingly high levels of advanced and deadly 
forms of heart disease affecting predominantly younger cases and 
women. Apart from a clear need to develop tailored detection and 
treatment strategies for those individuals unfortunate enough to 
develop clinically detectable forms of CVD, these data from the 
HOS have highlighted the importance of redoubling our efforts to 
prevent CVD in order to truncate what is shaping up to be a 
devastating epidemic in vulnerable communities subject to the 
profound effects of epidemiological transition. 
IdentIfyIng some of tHe cHALLenges                  
fAced In tHe preVentIon of cVd In A Low-       
resource enVIronment
Given the relative burden of CVD in low- to middle- income 
countries, it is unfortunate that most of our knowledge surrounding 
its prevention and treatment is derived from high-income countries 
with predominantly Caucasian populations. An ever-expanding 
body of research has facilitated the development of expert guide-
lines (e.g. those produced by the American Heart Association/ 
American College of Cardiology) to provide a comprehensive 
guide for the primary and secondary prevention of CVD.(19,20) 
Regardless of the environment, one of the key issues that continue 
to drive debate over the best way to optimise the primary pre-
vention of CVD focuses on cost-effective screening for modifiable 
risk factors (e.g. hypertension) as well as sub-clinical CVD (e.g. early 
signs of atherosclerosis as indicated by carotid intimal thickness or 
fIgure 1:  Profile of the 2006 Heart of Soweto Cohort(14)
De novo cases
N = 1 937 (43%)
Detailed clinical registry Simple clinical registry
De novo cases
N = 1 937 (43%)
Non-cardiac
N = 344 (18%)
Newly diagnosed CVD
N = 1 593 (38%)
Hypertension
N = 897 (56%)
Hypertension
N = 1 330 (52%)
Heart failure
N = 825 (52%)
Valvular heart disease
N = 976 (38%)
Valvular heart disease
N = 360 (23%)
Coronary artery disease
N = 451 (18%)
Previously treated CVD
N = 2 569 (62%)
Total Heart of Soweto Study population (2006) 
N = 4 506
Coronary artery disease
N = 184 (12%)
Heart failure
N = 184 (7%)
Other forms of CVD disease
N = 129 (8%)
Other forms of CVD disease
N = 94 (4%)
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asymptomatic left ventricular dysfunction detected by echo-
cardiography). Similarly, the thresholds for active intervention both 
at the individual and population level (e.g. particularly when 
considering borderline risk) on an age and sex-specific basis are not 
only open to debate but complicated by the choice between 
selective treatment versus application of the broader “polypill” 
approach.(21) Although the targets for secondary prevention are 
easier to identify, there are clearly many similar issues to be 
addressed before our approach in high-income countries, is 
optimised.(22) 
Any consideration of CVD prevention has to begin with the 
collation of risk factor and CVD profiling via community surveil-
lance programmes and collation of mortality and morbidity data 
wherever possible. In terms of a broad prevention strategy, both a 
“population-based” approach (reducing the burden of disease in 
the whole community while providing only small benefits to each 
individual)(23) and a “high-risk” approach (providing greater benefit 
to the most vulnerable individuals while offering limited benefits 
to the majority of the population - some of whom may derive 
immediate marginal or longer-term benefits from being actively 
treated)(24) have been advocated and both have some relevance to 
resource-deficient countries depending on the most prevalent 
modifiable risk factors and the type of intervention required to 
modify them. 
In practical terms, to effectively prevent and manage CVD in any 
environment there needs to be a balance between “population-
based” and “high-risk” approaches and a threshold for defining 
those at “high-risk” with adjustment of that balance (i.e. not an all 
or nothing approach) to reflect the circumstances. In low- to 
middle-income countries, an environment of limited healthcare 
resources makes the “high-risk” group approach a natural target. 
However, in such countries, there is often no organised pro-
gramme or scheme for screening and detecting these “high-risk” 
individuals.(24) The primary care sector (in whatever form), there-
fore, plays a critical role in providing effective delivery of cost-
effective interventions for CVD. The barrier for most low and 
middle-income countries is that human resources and infra-
structure capacity at primary level is unable (and in some cases 
instructed by governments and health departments) to upgrade 
their healthcare facilities to screen, diagnose and effectively treat 
the emergence of chronic conditions when confronted with the 
burden of infectious disease and other historical conditions. 
A multidrug regimen to address the most common risk factors has 
been proposed to be both cost-effective and reduce the occur-
rence of CVD by half in high risk individuals.(25-27) The concept of 
a “polypill” was introduced by Wald and Law and consisted of a 
statin (lipid-lowering), aspirin (anti-platelet), ß-blocker (anti-hyper-
tensive) an angiotensin-converting enzyme inhibitor (ACEI), a 
thiazide and folic acid.(25) Whilst the notion of “polypill” would 
undoubtedly improve adherence rates, the most effective combi-
nation of its constituents still remains heavily debated and unsub-
stantiated by clinical trials. The definition of what is cost-effective 
differs between countries, as well as from region to region within 
countries. In developing countries, the WHO recommendations 
indicate that for an intervention to be cost-effective in a particular 
region or country, it should be less than three times the gross 
national income per capita (GNI).(17) 
Poor access to quality healthcare services
Adding to the burden of chronic diseases, is the still persistent 
social and economical inequalities in South Africa due to past 
legacies of racial and gender discrimination, people having to work 
away from their homes and the resultant destruction of family life, 
income inequalities, and increased rates of crime and violence. 
Inadequate access to good-quality health services is still a reality for 
the poor due to financial constraints, having to travel far to 
healthcare centres and poor care from the healthcare system.(5,7)
AddressIng some of tHe cHALLenges                  
fAced wHen conductIng reseArcH In A            
Low-resource enVIronment
As described above, like many other parts of the world in sub-
Saharan Africa, the process of urbanisation has led to an increase in 
conventional CV risk factors such as obesity, hypertension and 
type 2 diabetes, resulting in alarming rates of CVD; a pattern that 
mimics the western world. For example, a systematic review of 
studies of hypertension in the region demonstrated a clear dif-
ferential between urban and rural regions; the latter demonstrating 
far lower prevalence of hypertension (i.e. consistent with historical 
lows) as a presumed result of continued adherence to traditional 
lifestyles. Despite the potential benefits of applying effective and 
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inexpensive treatment regimens for both primary and secondary 
prevention such treatments are frequently under-utilised in low- to 
middle-income countries.(28,29,30) Issues relating to lack of aware- 
ness of CVD, basing decisions on accurate risk factor profiling and 
the cost and complexity of developing systems of care to apply 
these seemingly cheap and simple options remain under-utilised 
even in high-income countries clearly need to be addressed if 
their potential is to be realised in truncating a rising epidemic of 
CVD in vulnerable communities.
funding support
In an endeavour to address the urgently required response to 
emergent CVD in the developing world, the Committee on 
Research, Development and Institutional strengthening for control 
of cardiovascular diseases in developing countries(31) outlined six 
broad areas for research and development that need to be 
addressed: 
 ■ Determine the magnitude of the CVD burden in developing 
countries.
 ■ Develop, targeted, effective primordial and primary prevention 
strategies using case-control studies.
 ■ Reduce tobacco use.
 ■ Detect and treat high blood pressure/hypertension.
 ■ Initiate pilot studies to evaluate essential vascular treatment for 
effective use of low-cost drugs.
 ■ Develop and assess algorithms of affordable clinical care for 
CVD.
The same committee called for capacity building in the following 
areas:
 ■ Population-based epidemiologic research.
 ■ Clinical research.
 ■ Health policy research.
 ■ Economic evaluation of healthcare interventions.
As with any research, a key factor in building research and clinical 
capacity is through multidisciplinary and international collabora-
tions. Currently, the WHO and various other philanthropic inter-
national agencies provide funding and sponsorship for researchers 
in low- to middle-income countries to forge collaborations with 
researchers and clinicians in high-income countries to tackle the 
emerging issue of non-communicable disease. Such opportunities 
obvious facilitate the establishment of research networks within 
and among developing countries to leverage scientific expertise and 
financial resources in order to establish world-class research 
facilities and training programmes. 
A systematic approach
In order to facilitate any attempt to quantify and then respond to 
the rapid emergence of non-communicable disease states such as 
CVD in low- to middle-income countries, the WHO has developed 
prioritised guidelines for disease surveillance. The WHO STEPwise 
approach to Surveillance (STEPS) is a simple, standardised method 
for collecting, analysing and disseminating data on non-com-
municable disease states. For example, the WHO STEPS stroke 
system(32) focuses on gathering equivalent data on the following 
within well-defined populations:
 ■ Stroke-related deaths in healthcare facilities (i.e. major tertiary 
centres).
 ■ Stroke-related deaths in the wider community.
 ■ Non-fatal hospital events related to stroke.
In the absence of a specific database, this approach (across the 
range of CVD states) is particularly helpful and has been success-
fully employed in Mozambique deriving invaluable data on the 
burden of strokes in that country.(33)
prActIcAL Lessons from tHe HeArt of              
soweto study
Given all of the above information, is it really possible to establish a 
combined public health and clinical research programme that is 
not only able to increase awareness of new forms of CVD (both 
within the public and health policy domain) but develop a cost-
effective screening programme that is built on capacity building 
and the development of new programmes of care? Whilst not 
perfect in any shape or form, or particularly unique (especially 
when considering high quality research programmes such as the 
THUSA – Transition and Health during Urbanisation of South 
Africans),(34) the SASPI (South African Stroke Prevention Initia- 
tive)(35) and the Agincourt project,(36) there is much to learn from 
the broad activities undertaken as part of the HOS.(6)
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Six useful lessons learnt from initiating and developing the HOS 
correlates with the timing of each key development in this study 
and should be interpreted with the previous section of the paper 
firmly in mind.
Building partnerships
Partnerships with a stronger research/clinical group 
In a resource-poor environment with untapped potential (in terms 
of research development and outputs), there is often the need for 
the “home” research/clinical team to develop a collaboration with 
a much stronger research/clinical group that can provide instant 
access to new sources of funding and, of course, bring to the table 
a combination of skills currently lacking. Not surprisingly, such 
collaboration will often involve an international research group with 
a substantial reputation and track record in the field. Two key 
ingredients are, however essential for a successful collaboration. 
The first of these is mutual respect, recognising the skill-sets and 
contributions of both sides. Another key ingredient to “harmo-
nising” such collaboration is establishing (in an open and honest 
manner) what the collaboration is about. A common purpose in 
addressing CVD within a target community or population yields 
capacity building, funding success and publications as joint rewards.
Partnerships with the community and other important role 
players in the community
When planning and implementing community-level activities, such 
as the “Heart Awareness Days”, it is important to get to know and 
be accepted by the local communities, key role players and 
organisations working in the area.
Establish clear objectives with achievable goals
One of the major dangers when operating within a challenged 
environment with clearly identifiable needs (e.g. a poorly under-
stood, but clearly large and evolving burden of CVD in a vulnerable 
community), is to immediately jump to the “end solution”. For 
example, when we first began thinking about the HOS in late 
2005, we had grandiose visions of the “African Framingham”. While 
not completely shelved, a much more orderly and achievable 
programme of public health activities (i.e. the simplistic, but highly 
successful “Heart Awareness Days” undertaken in key locations 
throughout Soweto) and clinical research focusing on a “con-
trolled” environment (i.e. the Cardiology Unit at Baragwanath 
Hospital in Soweto) was initially developed. Figure 2 shows how 
this initial programme of focusing on community screening (on a 
monthly basis) and tertiary cases of heart disease (on a continuous 
basis) has built the requisite systems and personnel to enable us 
to develop other key streams; including plans for a primary care 
registry and specific disease management programmes in 2009 and 
population screening in the not-too-distant future. A three to five 
year plan with clearly achievable goals is obviously worthwhile; 
success in small steps is much better than failure on a large scale.
Think big and assume nothing! 
Having warned of the dangers of jumping too far ahead and trying 
to achieve the impossible, it is worthwhile warning of the converse 
danger of thinking too small and too conservatively. The dangers of 
giving away invaluable research data (see point 1) and/or failure to 
truly develop something worthwhile (i.e. an internationally com-
petitive CV screening and prevention programme) is often under-
pinned by false assumptions that it is either all too hard or has all 
been done before. Despite initial reservations about the usefulness 
and potentially unique aspects of the HOS Clinical Registry, we 
have come to realise that it had value. For example, when we 
looked to replicate the larger data sets (e.g. the Euro Heart 
Survey)(37) that captured similar data in other parts of the world, 
tHE HEArt of SowEto Study
fIgure 1:  Key phases of development in the Heart of  
Soweto Study
Problem recognition
Initial focus: tertiary cases + community screening
Capacity building: resources & people
Key outputs: reports, clinical & research training + 
new services & facilities
HF 
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HIV/AIDS 
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Primary care 
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we realised that we were in a position to develop a meaningful 
system for classifying a complexity of CVD not seen or described 
outside Europe and North America. The mutual goal of our 
African-Australian collaboration is to achieve something unique 
to sub-Saharan Africa and the needs of the community of Soweto. 
Provide an enabling environment
Sufficient and reliable funding
As described previously, the level of philanthropic and global 
funding to support public health and clinical research into non-
communicable disease states such atherosclerotic disease and 
CVD arising from metabolic disorders (i.e. diabetes and obesity), 
smoking and hypertension in low- to middle-income countries is 
far behind that directed towards infectious diseases. Rather than 
tread the well-worn path to rejection and little output, it is 
worthwhile considering alternative sources of funding that may be 
initially small but then lead to greater funding; having established 
a stronger application for funding via compelling preliminary data. 
As such, a more entrepreneurial mindset is often required. Our 
novel approach to involve generic drug manufacturers who were 
interested in establishing a “presence” in the CVD market led to 
both direct funding and funding derived from their philanthropic 
arms. This proved useful when focusing on the community aspects 
of the “Heart Awareness Days” and producing “marketing friendly” 
products such as the study logo and educational pamphlets on 
heart disease. 
Investing in the right people
While funding is crucial to any effort, it is worthless without the 
right people to support a research or healthcare programme. The 
Heart of Soweto Study currently supports, rather than simply 
employ, a number of key individuals from a range of health 
disciplines. In each case, there is a focus on “investment” and 
personal growth to enable us to tackle the next phase of the 
overall research programme and related healthcare services. For 
example, we quickly identified the need to attract nurses with the 
clinical expertise to capture complex CV data, who were pre- 
pared to learn new skills and knowledge of clinical and public 
health research. Similarly, we have provided opportunities for 
nurses, dieticians, basic researchers and physicians alike to under-
take higher degrees and create their own opportunities within the 
framework of the programme. 
In the initial phases of a new research or healthcare programme 
(particularly when contemplating an ambitious screening pro-
gramme in challenging circumstances) there will always need to 
be clear “leaders” who develop the collaborations, set clear object-
ives, attract funding and invest in key personnel via supervision 
and mentorship. In the longer-term, it is essential that a true 
team approach emerge, where all members of the team are 
encouraged and given the opportunity to address all aspects of 
the programme in an open and constructive manner.
Innovative solutions
One of the most important aspects of operating within a resource-
poor and challenging environment is being prepared to experiment 
and fail in order to find a solution that is appropriate for that 
environment. In the early phases of the HOS, for example, we 
introduced a system of hand-held devices to capture clinical data 
electronically within an inherently chaotic environment. Our key 
expectations were that our dedicated research nurses would 
appreciate the flexibility of the system, data quality would be 
better than other paper-based methods and that data transfer 
and storage would be achieved without having to employ a specific 
data manager. As it turned out, we were wrong on all counts and 
spent a good three to four months exploring this option. How-
ever, the resulting system of paper capture via a semi-auto- 
mated approach to data entry (following clinical verification) has 
proved to be extremely satisfactory. As such, we have continued 
to consider the lessons of the past in designing the next phase of 
our research activities – a continent wide study of heart disease 
called the “Heart of Africa Study”. 
don’t compromise on quality 
In assessing our various systems and data arising from the HOS, 
we have never tolerated any excuse that would lead us to accept 
sub-standard outcomes. Naturally, in a resource-poor environ-
ment, potential excuses for poor quality research and healthcare 
relative to the rest of the world may be many and varied and often 
times seemingly perfectly legitimate. However, if you have set 
clear and achievable goals, attracted appropriate funding and 
invested in the right people and resources, there should be no 
excuse for accepting poor quality outcomes. Indeed, if adjusted 
to the particular needs of environment based on a logical and 
rationale plan of research or healthcare activities, even the simplest 
of programmes can be regarded as “world-class” and provide a 
valuable contribution to the literature.  
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future dIrectIons                                                         
The prevention of CVD and other chronic diseases of lifestyle, as 
well as the management thereof, need to be a multidisciplinary 
effort with all the necessary healthcare workers involved, imple-
mented at primary and secondary level. This should include specific 
risk factor profiling and trajectory of CVD in these resource-poor 
communities in epidemiologic transition, building on the HOS data 
and experiences. 
Long-term projects and key objectives
In-reach programme
Future long-term projects will include an “in-reach programme”, 
to extend the successful “Heart of Soweto Hypertension and 
Heart Failure Management Programme” into a broader “Chronic 
Disease Management Programme” to the remaining ten Soweto 
Primary Health Clinics. 
out-reach programme
An “out-reach programme” for African teenagers, to focus our 
research and education to a particular vulnerable group: African 
teenagers with poor knowledge of an affordable and culturally 
acceptable healthy lifestyle. As outlined above the obesity epidemic 
in South Africa start already in children and in particular teen- 
agers. Obesity results in hypertension and its long-term disabling 
or even deadly consequences heart failure, diabetes and stroke. 
We aim to establish a dedicated programme focussing on living a 
healthy life in children and teenagers supported by members of 
our multidisciplinary team. We aim to achieve this goal by using 
suitable, simple and youth appropriate education material. 
out-reach programme
A broader “out-reach programme”, to the general Soweto 
community, continuing with our very successful “Chronic Disease 
Awareness Days”, screening and documenting risk factors for 
chronic diseases of lifestyle and creating awareness on the 
prevention thereof. 
The goal is the development of specific community-based inter-
vention programmes directed towards prevention and manage-
ment of chronic diseases of lifestyle in Soweto and to document 
the aetiology, presentation and management thereof. In addition, 
we plan to develop an “African Cardiovascular Disease Risk 
Score”, intended to find application not only in Soweto, but also in 
other areas of Africa with an urban African population in transition. 
summAry                                                                         
In summary, there is ample evidence to suggest that the burden of 
CVD is already having a profound effect on the health of vulnerable 
populations in low- to middle-income countries of the world. The 
phenomenon of epidemiological transition has certainly contributed 
to the rise of CVD and will no doubt feed a sustained epidemic of 
non-communicable forms of CVD for the foreseeable future. 
Unfortunately, in resource poor countries there is often limited 
scope to respond to this growing problem. This is particularly 
exacerbated by a lack of awareness and funding to tackle CVD 
both at the national and international level. 
There is, however, still time to implement cost-effective primor-
dial, primary and secondary prevention strategies in low- to middle-
income countries in order to truncate the type of epidemic seen in 
high-income countries. Applying a practical and systematic approach 
in order to: (a) properly understand the problem (i.e. risk profile 
and spectrum of CVD within the local population), (b) health 
promotion strategies to deal with anticipated health risks, (c) adopt 
fundamental, low-cost treatment strategies, (d) build clinical and 
research capacity, (e) develop flexible surveillance programmes and 
(f) evaluate the impact of any implemented strategies from a local 
perspective, is the key to achieving sustainable and productive 
health outcomes within a resource-poor environment.   
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